Latest Content

The FDA accepted a new drug application for zidesamtinib for previously treated locally advanced or metastatic ROS1-positive non-small cell lung cancer.

Dr. Michael Staehler highlighted nutrition’s role in kidney cancer, noting that diet, stress management, and lifestyle can impact outcomes and well-being.

I reflect on my brain tumor journey, sharing how gratitude, love and connection with my parents and others strengthened me through difficult times.

The FDA has approved Hyrnuo for some with locally advanced or metastatic non-squamous non–small cell lung cancer with activating mutations.

The FDA approved Imdelltra after a study showed longer survival compared with chemotherapy in advanced small cell lung cancer.

I never dreamed a stranger could teach me so much about cancer, life and living with gratitude but I'm so glad she did!

Dr. Jorge E. Cortes discussed the evolution of chronic myeloid leukemia treatment and emerging strategies aimed at improving outcomes and quality of life.

The oral therapy DPTX3186 received fast track status to help speed development of a potential new option for patients with gastric cancer.

Dr. Pamela L. Kunz sat down with CURE to discuss Neuroendocrine Tumors, or NETs, Awareness Month.

Dr. Adam J. Schoenfeld delivered an extensive overview of how cellular therapies are shaping the future of lung cancer care.

Dr. Catherine A. Shu highlights targeted therapies for patients with lung cancer, emphasizing advances, challenges and the importance of clinical trials.

Many fail to recognize that estrogen is necessary to help your body and its parts work in concert with each other seamlessly.  

The FDA has granted fast track designation to ITM-94 as a diagnostic agent for the detection of the most common type of kidney cancer.